Physician profile
Jeffrey Cary
NPI 1235129131
$105,625.14
in general payments reported to CMS, 2019-2025
8 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $18K · 2021: $3,927 · 2022: $16K · 2023: $16K · 2024: $3,935 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $3,636 · Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,369.00 |
| Travel and Lodging | $3,636.35 |
| Food and Beverage | $756.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $50,310.07 | 2019-2024 | Yupelri, Yupelri |
| Sunovion Pharmaceuticals INC. | $35,417.87 | 2019-2020 | |
| Genentech USA, INC. | $17,450.73 | 2019-2020 | |
| Viatris Specialty LLC | $2,177.78 | 2025 | Yupelri |
| Boston Scientific Corporation | $165.68 | 2019-2024 | Ekosonic |
| Glaxosmithkline, LLC. | $53.06 | 2020 | |
| Genentech, INC. | $49.95 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.